A dengue vaccine cut hospitalisations 84% over 4.5 years, with real caveats

The dengue vaccine TAK-003 offers real, durable protection — strongest against the severe disease that lands children in hospital, and weaker against milder infection, especially in children who have never had dengue before. Over roughly 4.5 years of follow-up, two doses were 61.2% effective against symptomatic, laboratory-confirmed dengue (95% CI 56.0–65.8) and 84.1% effective against dengue that required hospitalisation (77.8–88.6) [s1].

Those figures come from the long-term results of a phase 3, randomised, double-blind, placebo-controlled trial that enrolled 20,099 healthy children and adolescents aged 4–16 at 26 centres across eight dengue-endemic countries: Brazil, Colombia, the Dominican Republic, Nicaragua, Panama, the Philippines, Sri Lanka and Thailand [s1]. Participants were assigned two-to-one to receive two doses of TAK-003 (13,401) or placebo (6,698) three months apart, and 18,257 of them — 91.0% — completed about 4.5 years of follow-up after the second dose [s1]. Across the trial, 1,007 of 27,684 febrile episodes were confirmed as dengue (560 in the placebo group, 447 among vaccine recipients), and 188 of those required hospitalisation (142 placebo, 46 vaccine) [s1].

The design is what gives those numbers weight. Participants were randomly assigned two-to-one to vaccine or placebo, stratified by age and region, and neither they nor the investigators knew which they received [s1]. Rather than waiting for participants to report illness, the trial ran active surveillance for febrile episodes and tested them by RT-PCR, so cases were confirmed in the laboratory rather than assumed [s1]. Efficacy was measured cumulatively, from the first dose out to about 4.5 years after the second — a long enough window to see whether protection holds up rather than fades after a season [s1].

Where the protection thins out

The headline averages hide the vaccine's most important limitation. In children who were dengue-naive at the start — those with no evidence of prior infection — efficacy fell to 53.5% against symptomatic disease (95% CI 41.6–62.9) and 79.3% against hospitalisation (63.5–88.2) [s1]. That matters because naive recipients are precisely the group in whom a dengue vaccine's safety is scrutinised most closely, after an earlier dengue vaccine was found to raise severe-disease risk in previously uninfected children.

Protection also varied by serotype. In an exploratory analysis, the vaccine showed efficacy against all four dengue serotypes among participants with prior infection [s1]. In dengue-naive participants, efficacy was demonstrated against DENV-1 and DENV-2, was not observed against DENV-3, and could not be evaluated against DENV-4 because too few cases occurred [s1]. In other words, the strong overall numbers rest heavily on the serotypes and the previously-infected participants where the vaccine works best, and the picture is genuinely mixed where the data thin out.

What it means for use

This is why the vaccine's authorised use is deliberately narrow. The vaccine — marketed as Qdenga — is licensed in some countries, and WHO recommends it only for children aged 6–16 in settings with high dengue transmission, where the balance of benefit against the residual uncertainties is most favourable [s2]. That targeting reflects the trial's own message: the vaccine is most valuable where infection is common, most people have already been exposed, and severe disease is the main threat.

The stakes are large. About half the world's population now lives at risk of dengue, with an estimated 100–400 million infections each year, and there is no specific treatment — care is supportive, and prevention still leans heavily on mosquito control [s2]. A vaccine that cuts hospitalisations by more than 80% over several years is a meaningful addition to that toolkit. But the honest summary is the one the trial supports: durable and strong against severe dengue, partial and serotype-dependent against mild disease, and narrower in the never-infected — which is why it is deployed by age and setting rather than offered to everyone [s1][s2].

This article is informational and is not medical advice.

Sources

• [s1] "Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial," The Lancet Global Health, 1 February 2024. https://doi.org/10.1016/S2214-109X(23)00522-3
• [s2] World Health Organization, "Dengue and severe dengue" (fact sheet). https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue